Phase 2 N=27 Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism
Autism
Primary: Number of Participants Reporting Improvement on the Clinical Global Impression — 1; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=119 Study of A-101 for the Treatment of Seborrheic Keratosis
Seborrheic Keratosis
Primary: Percentage of PLA Responders With Target Lesion Clear (PLA = 0) in Each Arm at Visit 8. — 22; 18; 1 Participants — p=<0.0001
Phase 2 N=151 A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
Plaque Psoriasis
Primary: Clinical Response of Success — 6; 4; 6; 1 Participants — p=0.3571
Phase 2 N=6 Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone
Fragile X-associated Tremor/Ataxia Syndrome
Primary: California Verbal Learning Test II (CVLT2) Trial 1-5 Free Recall Total Raw Score — 34.0; 33.5 score on a scale
Phase 2 N=16 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
Plaque Psoriasis
Primary: Proportion of Patients in the Study With HPA Axis Suppression — 1; 0; 10; 0 Participants
Phase 2 N=141 Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response in Breast and Axillary Lymph Nodes. — 16; 14; 21; 5 Participants
Phase 2 N=30 FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
Chronic Lymphocytic Leukemia
Primary: Clinical Response Rate at 3 Months — 29 Participants
Phase 2 N=30 Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia
Juvenile Myelomonocytic Leukemia
Primary: Percent Probability of Event-free Survival (EFS) — 83; 22 percent probability
Phase 2 N=756 Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Breast Cancer
Primary: False Negative Rate (FNR) for Sentinel Lymph Node (SLN) Surgery After Chemotherapy When at Least 2 SLNs Were Excised in Women Initially Presenting With Biopsy-proven cN1…
Phase 2 N=58 Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival (PFS) Until First Progression — 2.0; 5.7 months
Phase 2 N=39 Effects of Atomoxetine in Mild Cognitive Impairment
Mild Cognitive Impairment
Primary: Change in Interleukin 1 (IL 1-alpha) in Cerebrospinal Fluid (CSF) in Subjects With Mild Cognitive Impairment (MCI) Treated With Atomoxetine/Inactive Compound Compared to…
Phase 2 N=41 A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060
Atopic Dermatitis
Primary: Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 14 Full Analysis Set — -94; -100 Percent change — p=0.012
Phase 2 N=59 Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
Estrogen Receptor-negative Breast Cancer · HER2-negative Breast Cancer · Progesterone Receptor-negative Breast Cancer
Primary: Progression-free Survival (PFS) — 9.1 Months
Phase 2 N=63 Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
Myelofibrosis
Primary: Rate of Non-relapse Mortality at 100 Days Post-transplant — 1; 2; 1 Participants
Phase 2 N=70 Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate
Rheumatoid Arthritis
Primary: Change From Baseline in Simple Disease Activity Index (SDAI) Score at Week 8 — 45.15; 44.85; -26.11; -17.38 units on a scale — p=<0.001